First Trust NASDAQ Cybersecurity ETF (NASDAQ: CIBR)

Ultime notizie per First Trust NASDAQ Cybersecurity ETF (NASDAQ:CIBR)

First Trust NASDAQ Cybersecurity ETF

Technology

Industrials

Financial Services

To achieve its investment objectives, The Nasdaq CTA Cybersecurity Index is designed to track the performance of companies engaged in the cybersecurity segment of the technology and industrials sectors. It includes companies primarily involved in the building, implementation, and management of security protocols applied to private and public networks, computers, and mobile devices in order to provide protection of the integrity of data and network operations.

Broadcom, Inc. (purchase Right At $290.00 Per Share) (5)

Crowdstrike Holdings Inc

Cisco Systems, Inc.

Palo Alto Networks Inc.

Infosys, Adr

Darktrace Plc

Thales S.A.

Gen Digital Inc

Leidos Holdings, Inc.

Booz Allen Hamilton Holding Corp.

Cloudflare Inc

Check Point Software Technologies Ltd.

Fortinet, Inc.

Cyberark Software

Wiz,And,Alphabet,Company,Logos,Seen,On,The,Smartphone,And

Sector ETFs

Tech

ETFs

AMZN

CIBR

GOOGL

HACK

MSFT

L&#39;acquisizione da $32 miliardi potrebbe innescare una nuova ondata di M&amp;A nel settore, favorendo fondi specializzati. Ecco l&#39;analisi.

Accordo Google-Wiz: 3 ETF pronti a decollare legati alla cybersicurezza

News

Analyst Ratings

Trading Ideas

TOST

Live On CNBC, Josh Brown Announces Bought More Toast, Inc.

Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares flashed a technical warning sign last week, and it didn't take long for the chatter to pick up. The stock triggered what's known as a &#8220;death cross&#8221; on March 20. That signal often suggests a potential downtrend, especially after the kind of monster run Nvidia has had.
Since October 2022, Nvidia has surged 948%, so this kind of chart movement grabbed attention. But not everyone is convinced it spells doom.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>This startup is on the brink of a huge disruption to a $654 billion industry – <a href="https://www.benzinga.com/money/venhub-adv">invest in it for under $10 before it's too late</a>.</li>
</ul>
<h2 class="wp-block-heading">Not The First Rodeo For Nvidia</h2>
Back in April 2022, Nvidia also flashed a death cross, and the stock went on to fall 47% before bottoming out. Naturally, investors are wondering if history is about to repeat itself.
While analysts are debating what the signal means, Jim Cramer took a more blunt approach. On March 21, the CNBC host <a href="https://x.com/jimcramer/status/1903125197911400722">posted</a> on X: &#8220;Are the zero-day put options holders blowing them out or pressing their bet because of the death cross. I ask because they don&#8217;t know the difference between Nvidia and Nivea.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Are the zero day put options holders blowing them out or pressing their bet because of the death cross. I ask because they don&#39;t know the difference between Nvidia and Nivea
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1903125197911400722?ref_src=twsrc%5Etfw">March 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
It was classic Cramer—mixing market commentary with sarcasm. His post suggested that many traders are reacting without truly understanding the stock or the signal.
In January, <a href="https://www.benzinga.com/markets/equities/25/01/42866458/jim-cramer-cites-nvidias-6-decline-to-too-much-hot-money-after-jensen-huangs-ces-keynote-watch-this-data-to-buy-stock-much-lower">Cramer urged investors</a> to consider Nvidia&#8217;s stock decline as a buying opportunity, saying, &#8220;Understand one thing, the keynote dazzled, the new projects are way ahead of any other company, and this new industrial revolution belongs to Nvidia.&#8221;
Zero-day options, especially puts, are popular among short-term speculators. Whether they're making sharp calls or just following headlines remains to be seen. But Cramer's point was that not every bearish bet is well-informed.
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
For now, Nvidia is holding up. After dipping briefly, <a href="https://www.benzinga.com/markets/equities/25/03/44388080/nvidia-shares-up-over-3-after-key-signal-reversing-early-decline">shares bounced back</a> a little bit. Whether that death cross turns into something bigger or just becomes a blip on the radar will depend on how the market—and Nvidia's fundamentals—evolve in the coming weeks.
<h2 class="wp-block-heading">What Is a Death Cross and Why Does It Matter?</h2>
A &#8220;death cross&#8221; happens when a stock&#8217;s short-term moving average, typically the 50-day, falls below its long-term average, often the 200-day. It can be seen as a sign that momentum is fading and that the stock might be entering a longer-term downtrend. While it&#8217;s not always a sign of trouble ahead, it tends to get attention from technical analysts and traders looking for signals about where the market might be headed next.
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

NVDA

'Death Cross' Panic? Jim Cramer Wonders If Zero-Day Puts Are Driven By Confusion. 'They Don't Know The Difference Between Nvidia and Nivea'

Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) has outperformed the market over the past 5 years by 13.09% on an annualized basis producing an average annual return of 30.13%. Currently, Insight Enterprises has a market capitalization of $5.10 billion. 
Buying $100 In NSIT: If an investor had bought $100 of NSIT stock 5 years ago, it would be worth $396.27 today based on a price of $160.42 for NSIT at the time of writing.
<h3>Insight Enterprises's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742920208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NSIT

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Jiangsu Hengrui Pharmaceuticals Co., Ltd on Tuesday entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">clinical trial in China</a>.
Lipoprotein (a), or Lp(a), is a type of lipoprotein produced in the liver that carries cholesterol, fats, and proteins in the blood.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" rel="noreferrer noopener">Pharmaceutical Firms Say UK Investment Is &#8216;Unlikely&#8217; Unless Payment Levy Is Adressed</a>
Lp(a) can accumulate in blood vessel walls, forming atherosclerotic plaques similar to LDL cholesterol. These plaques can limit blood flow to vital organs and result in conditions such as heart attack, stroke, and other cardiovascular diseases.
Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44470230/merck-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoprotein-a-inhibi" rel="noreferrer noopener">Greater China region</a>.
Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.77 billion and royalties on net sales of HRS-5346 if approved.
The transaction is expected to close in the second quarter of 2025.
Merck expects to record a pre-tax charge of $200 million, or approximately $0.06 per share, to be included in GAAP and non-GAAP results in the quarter the transaction closes.
Price Action: MRK stock is down 1.82% at $90.63 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/03/44470278/shell-unveils-new-strategy-higher-buybacks-cost-cuts-and-10-annual-free-cash-flow-growth" target="_blank" rel="noreferrer noopener">Shell Unveils New Strategy: Higher Buybacks, Cost Cuts And 10% Annual Free Cash Flow Growth</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Contracts

General

Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment

<a href="https://www.wsj.com/politics/policy/trump-administration-plans-to-freeze-family-planning-grants-541441be?mod=latest_headlines">https://www.wsj.com/politics/policy/trump-administration-plans-to-freeze-family-planning-grants-541441be?mod=latest_headlines</a>
The Trump administration is moving to freeze tens of millions of dollars in federal family-planning grants to certain organizations while it investigates whether the money was used for diversity efforts, people familiar with the matter said.&nbsp;
The groups that would be subject to the freeze, which include Planned Parenthood affiliates, were set to get about $120 million this year.

'Trump Administration Plans To Freeze Family-Planning Grants; Tens Of Millions Of Dollars In Funding For Planned Parenthood And Other Groups Would Be Cut Off While The Administration Examines Their DEI Efforts' - WSJ

Live On CNBC, Rob Sechan Announces Bought More Nvidia

Truist Securities analyst Scot Ciccarelli maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Buy and lowers the price target from $83 to $76.

Price Target

DLTR

Truist Securities Maintains Buy on Dollar Tree, Lowers Price Target to $76

Politics

Legal

Events

Boeing CEO To Appear Before Senate Committee On Commerce, Science And Transportation On April 2

Investors with significant funds have taken a bearish position in Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in TER usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 17 options transactions for Teradyne. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 5% being bullish and 52% bearish. Of all the options we discovered, 16 are puts, valued at $795,688, and there was a single call, worth $26,200.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $130.0 for Teradyne during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Teradyne's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Teradyne's substantial trades, within a strike price spectrum from $100.0 to $130.0 over the preceding 30 days.
<h3>Teradyne 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742919450_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.9</td>
<td>$17.8</td>
<td>$17.78</td>
<td>$100.00</td>
<td>$90.7K</td>
<td align="right">110</td>
<td align="right">294</td>
</tr>
<tr>
<td>TER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.6</td>
<td>$17.8</td>
<td>$17.85</td>
<td>$100.00</td>
<td>$75.0K</td>
<td align="right">110</td>
<td align="right">576</td>
</tr>
<tr>
<td>TER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$17.8</td>
<td>$17.7</td>
<td>$17.75</td>
<td>$100.00</td>
<td>$72.8K</td>
<td align="right">110</td>
<td align="right">61</td>
</tr>
<tr>
<td>TER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.8</td>
<td>$17.7</td>
<td>$17.78</td>
<td>$100.00</td>
<td>$67.5K</td>
<td align="right">110</td>
<td align="right">166</td>
</tr>
<tr>
<td>TER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.8</td>
<td>$17.7</td>
<td>$17.78</td>
<td>$100.00</td>
<td>$64.0K</td>
<td align="right">110</td>
<td align="right">781</td>
</tr>
</tbody>
</table>

<h3>About Teradyne</h3>
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Having examined the options trading patterns of Teradyne, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Teradyne Standing Right Now?</h3>
<ul>
<li>With a trading volume of 530,072, the price of TER is down by -1.21%, reaching $89.9.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Teradyne</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $128.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Teradyne with a target price of $155. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Hold rating for Teradyne, targeting a price of $110. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Teradyne, which currently sits at a price target of $130. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Teradyne, which currently sits at a price target of $110. 
&#x2A; An analyst from Vertical Research downgraded its action to Buy with a price target of $135. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teradyne with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Teradyne

Financial giants have made a conspicuous bullish move on Salesforce. Our analysis of options history for Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) revealed 53 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $1,259,452, and 35 were calls, valued at $1,746,099.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $430.0 for Salesforce over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Salesforce's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Salesforce's substantial trades, within a strike price spectrum from $100.0 to $430.0 over the preceding 30 days.
<h3>Salesforce Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742919444_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.7</td>
<td>$260.00</td>
<td>$441.0K</td>
<td>7</td>
<td align="right">300</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.95</td>
<td>$12.75</td>
<td>$12.75</td>
<td>$290.00</td>
<td>$118.5K</td>
<td>1.4K</td>
<td align="right">9</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$13.2</td>
<td>$12.85</td>
<td>$12.8</td>
<td>$270.00</td>
<td>$111.4K</td>
<td>1.1K</td>
<td align="right">108</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$26.5</td>
<td>$26.2</td>
<td>$26.2</td>
<td>$350.00</td>
<td>$94.3K</td>
<td>700</td>
<td align="right">36</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$147.2</td>
<td>$145.05</td>
<td>$145.95</td>
<td>$160.00</td>
<td>$72.9K</td>
<td>81</td>
<td align="right">72</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
In light of the recent options history for Salesforce, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Salesforce</h3>
<ul>
<li>Currently trading with a volume of 1,633,796, the CRM's price is up by 0.66%, now at $287.84. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 64 days.</li>
</ul>
<h3>Expert Opinions on Salesforce</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $322.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Macquarie persists with their Neutral rating on Salesforce, maintaining a target price of $320. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Salesforce with a target price of $350. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for Salesforce, targeting a price of $345. 
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Neutral rating on Salesforce with a target price of $320. 
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Neutral rating for Salesforce, targeting a price of $275. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Salesforce, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on CRM Options

Deep-pocketed investors have adopted a bullish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $132,526, and 5 are calls, amounting to $421,821.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $70.0 for CVS Health, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $30.0 to $70.0, over the past month.
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742919439_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.95</td>
<td>$5.85</td>
<td>$5.9</td>
<td>$62.50</td>
<td>$259.6K</td>
<td>4.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$1.12</td>
<td>$1.11</td>
<td>$1.12</td>
<td>$60.00</td>
<td>$53.5K</td>
<td>61</td>
<td align="right">439</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.0</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$62.50</td>
<td>$48.7K</td>
<td>4.1K</td>
<td align="right">750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.76</td>
<td>$2.66</td>
<td>$2.73</td>
<td>$65.00</td>
<td>$48.5K</td>
<td>2.8K</td>
<td align="right">237</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.85</td>
<td>$0.83</td>
<td>$0.85</td>
<td>$70.00</td>
<td>$42.5K</td>
<td>3.5K</td>
<td align="right">646</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>With a volume of 3,195,679, the price of CVS is down -1.4% at $66.62. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $74.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on CVS Health, maintaining a target price of $74. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CVS Health, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

CVS Health Unusual Options Activity

AppLovin Corp.&nbsp;(NASD: APP) shares are higher on Tuesday.&nbsp;The stock has gained more than $100 in just three weeks. There is a good chance this uptrend stays intact.
The shares have just broken out and may be about to refill a gap. This is why it is our Stock of the Day.
Resistance is a price or zone where there is a significant amount of sell interest.
If a stock is trending higher, it's because there aren't enough sell orders to fill all the buy orders. Those who wish to buy are forced to outbid each other. This pushes the price higher.
When a stock reaches a resistance level, the dynamic changes. There are enough shares for sale to fill all of the buy orders. People who wish to buy can purchase as many shares as they want without the price moving up.
Sometimes, the resistance eventually breaks. The buyers overpower the sellers and drive the price higher. Breakouts tend to be bullish. They show the traders and investors who created the resistance with their sell orders have left the market, either canceling or finishing them.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25121602/Applovin1-1024x552.png" alt="" class="wp-image-840906" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25121602/Applovin1-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25121602/Applovin1-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25121602/Applovin1-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25121602/Applovin1.png 1519w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: <a href="https://www.benzinga.com/government/regulations/25/03/44475192/consumer-confidence-falls-to-lowest-since-2022-as-inflation-tariff-worries-grow">Consumer Confidence Falls To Lowest Since 2022 As Inflation, Tariff Worries Grow</a>
With this large amount of supply taken off of the market, buyers may have to start outbidding each other to draw sellers back in. This could force the shares into a new uptrend.
One of the main reasons why there is resistance in a market is buyer remorse. People buy shares, but then regret doing so if the price falls after. Many decide that if they can eventually exit their positions at breakeven, they will.
So, it the stock rallies back to its buy price, investors place sell orders. If there is a large enough number of these sell orders, what had been a support level can turn into a resistance level. This is what happened at the $311 level with AppLovin.
When stocks rapidly fall through price levels like AppLovin did in February, there isn't enough time spent at these levels to create large groups of remorseful buyers who will be trying to sell on the way back up.
When the stock gets back to these prices going in the opposite direction, buyers may have a hard time finding sellers. They may need to be aggressive and push the price higher.
This could lead to a rapid move up. The uptrend in AppLovin may continue.
Read Also: • <a href="https://www.benzinga.com/government/regulations/25/03/44473410/trumps-tariff-rates-could-be-double-what-market-participants-expect-goldman-sachs-warns">Trump&#8217;s Tariff Rates Could Be &#8216;Double What Market Participants Expect,&#8217; Goldman Sachs Warns</a>
Photo: Shutterstock

Technicals

Stock Of The Day: Is AppLovin Headed Even Higher?

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 11.84% on an annualized basis producing an average annual return of 22.62%. Currently, Taiwan Semiconductor has a market capitalization of $935.91 billion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 10 years ago, it would be worth $7,761.29 today based on a price of $180.45 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742919414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 50 points on Tuesday.
The Dow traded down 0.06% to 42,556.82 while the NASDAQ climbed 0.29% to 18,241.49. The S&amp;P 500 also rose, gaining, 0.06% to 5,770.81.
Check This Out: <a href="https://www.benzinga.com/25/03/44471817/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Communication services shares jumped by 1.3% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.6%.
Top Headline
Sales of new single-family homes increased 1.8% to an annual rate of 676,000 in February, following a revised 6.9% decline in the previous month, and down from market estimates of 680,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares shot up 287% to $3.79 on possible continued strength after the company announced yesterday that it has received FDA 510(k) clearance for its Catamaran St Joint Fusion System.</li>
<li>Shares of DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>)got a boost, surging 140% to $5.18 after the company announced its Myseum social media platform is available on Apple iOS and Android.</li>
<li>BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) shares were also up, gaining 12% to $4.9970 after the company reported a FY24 GAAP EPS beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares dropped 58% to $1.6050 after the company announced it will discontinue its final analysis of Nemvaleukin in combination with KEYTRUDA and will cease further development. Jones Trading downgraded the stock from Buy to Hold.</li>
<li>Shares of CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) were down 60% to $1.3499 after the company announced primary analysis of Berubicin in second line treatment of glioblastoma multiforme.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) was down, falling 32% to $7.32 following fourth-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $69.50 while gold traded up 0.7% at $3,037.10.
Silver traded up 2.4% to $34.235 on Tuesday, while copper rose 1.8% to $5.1825.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.76%, Germany's DAX 40 rose 0.80% and France's CAC 40 rose 1.02%. Spain's IBEX 35 Index rose 1.10%, while London's FTSE 100 gained 0.74%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.46%, China's Shanghai Composite Index falling 0.002%, Hong Kong's Hang Seng Index falling 2.35% and India's BSE Sensex gaining 0.04%.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index increased 4.7% year-over-year in January, versus a 4.5% increase in December, but down from market estimates of a 4.8% increase.</li>
<li>The FHFA house price index rose by 0.2% in January.</li>
<li>Sales of new single-family homes increased 1.8% to an annual rate of 676,000 in February, following a revised 6.9% decline in the previous month, and down from market estimates of 680,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44472214/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

CNSP

CRMD

DATS

FUFU

MURA

TNON

Nasdaq Gains 50 Points; US New Home Sales Rise In February

Shares of Alliance Entertainment Holding Corporation (AENT) are <a href="https://www.benzinga.com/movers">trading higher</a> on Tuesday.
The distributor — known for its focus on music, movies, video games, electronics, and collectibles — placed a <a href="https://www.benzinga.com/pressreleases/25/03/g44472031/alliance-entertainment-wins-bid-to-acquire-key-assets-from-diamond-comic-distributors">successful bid to purchase</a> the assets of bankrupt Diamond Comic Distributors, Inc.
Pending approval from the Bankruptcy Court, this acquisition encompasses Diamond Comic Distributors (U.S.), Alliance Game Distributors, Diamond Select Toys &amp; Collectibles, and Collectible Grading Authority. 
The move will broaden Alliance Entertainment's presence in the pop culture and collectibles market, a sector worth more than $50 billion.
Also Read: <a href="https://www.benzinga.com/25/03/44457612/tilrays-hiball-energy-returns-to-whole-foods-market-details">Tilray&#8217;s Hi&#x2A;Ball Energy Returns To Whole Foods Market</a>
The acquisition would grant Alliance Entertainment entry into a vast market, connecting it with over 5,000 retail locations, including independent comic stores, large retail chains, and online platforms. 
The involved businesses are key players in comics, tabletop games, and collectible grading, collaborating with major industry names like Dungeons &amp; Dragons, Pokémon, Marvel, and others. 
Diamond Comic Distributors flagship catalog, PREVIEWS, is distributed monthly to 30,000+ readers. The acquisition is expected to enhance Alliance's footprint in the growing tabletop games sector. It has more than 15,000 SKUs distributed to over 3,000 independent retailers across North America.
Furthermore, Collectible Grading Authority offers essential authentication and grading services to Alliance Entertainment, having certified more than 500,000 collectibles globally. 
This acquisition will allow Alliance to utilize Diamond's intellectual property across its mass retail and online platforms. It will also introduce its vast collection of physical media to thousands of niche retailers.
The deal is anticipated to be finalized in April 2025, pending final approval from the bankruptcy court. Alliance held <a href="https://www.benzinga.com/pressreleases/25/02/g43711648/alliance-entertainment-reports-second-quarter-fiscal-year-2025-results">$2.5 million in cash and equivalents</a> as of Dec. 31, 2024.
Price Action: AENT shares traded higher by 4.09% at $4.07 at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44457658/clearlake-capital-acquires-data-company-dun-bradstreet-in-77b-deal">Dun &amp; Bradstreet To Go Private In $7.7 Billion Clearlake Deal</a></li>
</ul>
Image: Shutterstock

AENT

Alliance Entertainment Wins Bid to Acquire Diamond Comic Distributors, Stock Gains

Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/CHWY/earnings">opening bell, on Wednesday, March 26</a>.
Analysts expect the Plantation, Florida-based company to report quarterly earnings at 20 cents per share, up from 18 cents per share in the year-ago period. Chewy projects quarterly revenue of $3.2 billion, up from $2.83 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 12, 2024, Chewy announced a public offering of Class A common stock by a selling stockholder and a concurrent share repurchase.
Chewy shares gained 0.5% to close at $34.02 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/chwy/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Seaport Global analyst Aaron Kessler initiated coverage on the stock with a Neutral rating on March 24, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citizens Capital Markets analyst Nicholas Jones reiterated a Market Outperform rating with a price target of $37 on March 21, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Wedbush analyst Seth Basham reiterated an Outperform rating with a price target of $39 on March 17, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Evercore ISI Group analyst Mark Mahaney upgraded the stock from In-Line to Outperform and raised the price target from $34 to $47 on Jan. 13, 2025. This analyst has an accuracy rate of 81%.</li>
<li>JMP Securities analyst Nicholas Jones reiterated a Market Outperform rating with a price target of $37 on Dec. 16, 2024. This analyst has an accuracy rate of 79%.</li>
</ul>
Considering buying CHWY stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44457888/top-2-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 2 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Earnings

CHWY

Chewy Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

<a href="https://developer.nvidia.com/blog/accelerating-the-future-of-transportation-with-ses-ais-nvidia-powered-innovation-for-electric-vehicles/">https://developer.nvidia.com/blog/accelerating-the-future-of-transportation-with-ses-ais-nvidia-powered-innovation-for-electric-vehicles/</a>
Electric vehicles (EVs) are transforming transportation, but challenges such as cost, longevity, and range remain barriers to widespread adoption. At the heart of these challenges lies battery technology—specifically, the electrolyte, a critical component that enables energy storage and delivery. The electrolyte's properties directly impact a battery's charging speed, power output, stability, and safety.
To overcome these hurdles, researchers are turning to AI-driven approaches to accelerate the discovery of novel battery materials.&nbsp;
SES AI, a leader in battery innovation, is leveraging the cutting-edge NVIDIA hardware and software ecosystem to revolutionize materials discovery. ​​By combining domain-adapted LLMs with an AI model and GPU-accelerated simulations in a single workflow, SES AI compresses decades of research into months and unlocks groundbreaking advancements in EV battery performance.&nbsp;
 &nbsp;

'Accelerating The Future Of Transportation With SES AI's NVIDIA-Powered Innovation For Electric Vehicles' - Nvidia

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>), a leading provider of Human Capital Management (HCM) software solutions, today highlighted exciting innovations emerging from its strategic partnership with Amazon Web Services (AWS), focused on leveraging advanced AI technologies and services. This collaboration underscores Asure's commitment to driving transformative advances in HR and payroll solutions through artificial intelligence.
Highlighted recently on AWS's prominent machine learning blog, this partnership showcases how the integration of generative AI tools, such as Amazon Q in QuickSight, opens the door to groundbreaking possibilities across numerous business functions. While the current focus demonstrates a transformative shift in call center operations, the broader vision of this collaboration extends well beyond customer support. Future innovations made possible through generative AI and AWS services include predictive HR analytics, intelligent workforce management, personalized employee engagement platforms, and advanced compliance monitoring.

ASUR

Asure Software Highlights Innovations Emerging From Its Strategic Partnership With Amazon Web Services, Focused On Leveraging Advanced AI Technologies And Services

CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">form of brain cancer</a>.
The trial compared Berubicin to Lomustine, a current standard of care in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44471506/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-second-line-treatment-of-glioblast" rel="noreferrer noopener">recurrent or progressive GBM</a>.
This analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
Additionally, patients experienced no cardiotoxicity, a risk that curtails the use of other anthracyclines, and the safety profile continues to be favorable in this patient population.
The company says the data appear comparable to Lomustine in important clinically relevant endpoints, including overall survival (OS) and progression-free survival (PFS) across all patients treated with Berubicin.
&#8220;Because of the cardiotoxicity associated with other anthracyclines,&#8221; said Sandra Silberman, chief medical officer of CNS Pharmaceuticals, &#8220;the fact that this study showed no cardiotoxicity with Berubicin, even in those receiving the drug for over a year, suggests Berubicin could be a valuable recourse for patients with recurrent or progressive cancers.&#8221; 
&#8220;Berubicin also did not exhibit the pulmonary toxicity or the thrombocytopenia associated with Lomustine, suggesting it could be a way for patients to avoid those side effects during treatment. Furthermore, its primary mechanism of action, topoisomerase II inhibition, is agnostic to specific tumor histology, making it a potentially more generalizable therapy,&#8221; she added.
As of Feb. 26, 2025, the company&#8217;s current cash position has increased to $14 million. Based on current projections, management believes the current cash on hand is sufficient to <a href="https://www.benzinga.com/pressreleases/25/02/ac43972994/cns-pharmaceuticals-provides-update-on-current-cash-position-and-nasdaq-listing" target="_blank" rel="noreferrer noopener">fund operations into 2026</a>.
Price Action: CNSP stock is down 59.9% at $1.37 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/mid-cap/25/03/44462576/bofa-calls-generac-buy-blackouts-grid-reliability" target="_blank" rel="noreferrer noopener">Generac Poised To Benefit From Blackouts, Declining Grid Reliability: BofA Analyst</a></li>
</ul>
Photo: Shutterstock

Movers

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Copper just blew past record highs, dismissing recent recession fears as stimulus optimism in China and potential U.S. tariffs spark a rush <a href="https://www.benzinga.com/markets/commodities">into the red metal.</a>
Copper futures traded at the New York Mercantile Exchange rallied 1.6% to $5.17 per pound on Tuesday, notching historical records. 
<h1 class="wp-block-heading">What's Fueling Copper's Relentless Climb?</h1>
Often dubbed &#8220;Dr. Copper&#8221; for its reputation as a proxy for global industrial health, the metal has surged as traders bet on a brighter economic outlook in China and react to tariff risks.
"Tariff threats, tightening supply, and stimulus-fueled optimism for an economic rebound in China have underpinned a rally in copper," said Adam Turnquist, chief technical strategist for LPL Financial. 
&#8220;Beijing's pro-growth agenda is beginning to show up in the economic data, evidenced by recent better-than-expected retail sales, industrial output, and fixed-asset investment,&#8221; he added.
Turnquist indicated markets are already "front-running" the potential copper tariff ordered under former President Donald Trump's direction, even though an official recommendation isn't expected until later this year.
Bloomberg data shows that between 100,000 and 150,000 metric tons of copper are en route to the U.S., the highest inbound volume on record. That flood of demand has pushed the COMEX copper premium over LME copper to its highest point ever, indicating intense physical buying interest in the U.S. market.
David&nbsp;Goldman, head of trading at Novion Global, also pointed to dollar weakness as a factor boosting copper prices. 
&#8220;Whilst LME&nbsp;copper&nbsp;is up around 14% from the start of the year, COMEX prices have seen a 27% jump, prompting traders and producers to move supplies to the US,&#8221; he said.
&#8220;The price squeeze is also being replicated on the Shanghai Futures Exchange, where the front month spread is trading at levels not seen since December 2023.&#8221;
<h1 class="wp-block-heading">China&#8217;s Recovery and Strategic Buying Add Fuel to the Fire</h1>
Adding further momentum is a shift in tone out of Beijing. Goldman Sachs analyst Daan Struyven said, "China sentiment has turned notably more positive" thanks to the government's focus on boosting household consumption, lower-than-expected U.S. tariffs and a surge of investor excitement around artificial intelligence.
Importantly, Struyven flagged reports that China's State Reserve Bureau plans to replenish copper stockpiles in 2025. While not purely opportunistic, this buying could cushion any price-sensitive demand drop in China. 
"We remain structurally bullish," said Struyven, who sees the LME's ongoing tightening and strong electrification trends driving prices higher in the months ahead.
<h1 class="wp-block-heading">Copper Chart Breaks Out — And So Do The Stocks</h1>
The price move has also broken a key technical level. 
According to LPL Financial's Turnquist, copper futures have surged past the highs of 2021–2022, completing a "head and shoulders" bottom pattern that hints at more upside ahead. 
Speculative flows are also favoring the bulls. Hedge funds and other large speculators have largely unwound their short positions, while long bets have picked up in recent months, supporting the momentum.
That enthusiasm has spilled into equity markets. Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), one of the world's largest copper producers, has climbed 13% in March, on track for its best monthly performance in a year. Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) is also up 12% over the same period, riding the wave of investor optimism.
Traders looking for broad copper exposure may consider the Global X Copper Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>), which has historically showed strong rallies April. Over the past 15 years, the ETF has gained an average of 4.5% during the month — its strongest seasonal trend of the year.
Read Next: •<a href="https://www.benzinga.com/government/regulations/25/03/44463509/ukraines-recovery-depends-on-sustainable-investment-experts-call-for-trilateral-minerals-deal"> &#8216;Ukraine&#8217;s Recovery Depends On Sustainable Investment,&#8217; Experts Call For Trilateral Minerals Deal</a>
Photo: Shutterstock

Analyst Color

Government

Macro Economic Events

Regulations

Global

Economics

COPX

SCCO

Copper Breaks Records On China Stimulus, Tariff Hype: These Stocks Are Riding The Wave

Comments

First Trust NASDAQ Cybersecurity ETF

Notizie

Ultime notizie per First Trust NASDAQ Cybersecurity ETF (NASDAQ:CIBR)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO